Literature DB >> 11324756

Large envelope glycoprotein and nucleocapsid protein of equine arteritis virus (EAV) induce an immune response in Balb/c mice by DNA vaccination; strategy for developing a DNA-vaccine against EAV-infection.

E Tobiasch1, R Kehm, U Bahr, C A Tidona, N J Jakob, M Handermann, G Darai, M Giese.   

Abstract

Equine arteritis virus (EAV) is a member of the Arteriviridae family, that includes lactate dehydrogenase-elevating virus (LDV), porcine reproductive and respiratory syndrome virus (PRRSV), and simian haemorrhagic fever virus (SHFV). Equine arteritis is a contagious disease of horses and is spread via respiratory or reproductive tract. The objective of the present study is to evaluate the possibility for developing a model system for prevention horses against an EAV infection by DNAvaccination. A cDNA bank from the RNA of EAV was established. This gene library contains the translation unit of the EAV open reading frames (ORF) 1 to 7. The identity of the cDNA was confirmed by nucleotide sequence analysis. Using this defined EAV cDNA gene library the cDNA sequence of the viral ORFs were molecularly cloned into the corresponding sites of well characterized and powerful expression vectors (pCR3.1, pDisplay, and/or pcDNA3.1/HisC). The capability of these recombinant plasmids expressing the gene products of the individual viral ORFs 3 to 5, and 7 in induction of an immune response in mouse system was investigated. The Balb/c mice (ten mice per assay) were inoculated with the DNA of the constructed expression vectors harboring and expressing the EAV cDNA of the viral ORFs. The Balb/c mice were injected with about 100 microg DNA diluted in 100 microl PBS. The DNA was injected subcutaneously and into the tibialis cranialis muscle (Musculus gastrocnemius). The mice were boosted 3 to 5 times with the same quantities of DNA and under the same conditions at about two week intervals. Control mice received the same amount of parental expression vectors via an identical route and frequency. The pre- and post-vaccinated sera of the individual animals were screened by neutralization tests (NT). Neutralizing antibodies against EAV were detected when the animals were inoculated with the DNA of the expression vectors harboring cDNA of the EAV ORFs 5 and 7. Highest NT-titers were observed when the animals were administered with the cDNA of ORF 5 and/or with the cDNA of the neutralization determinants of EAV that is located on the N-terminal ectodomain of the gene product of ORF 5 between the amino acid positions 1-121. These results obtained from these studies justified proofing the capability of the EAV cDNA sequences of the viral genes including ORFs 5 and 7 in the autologous animal system horse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11324756     DOI: 10.1023/a:1008175525254

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  22 in total

Review 1.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

2.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

3.  Comparative analysis of the transcripts mapped in the BamHI DNA fragment B of avirulent HSV-1 HFEM, virulent HSV-1 F, and their intratypic recombinant viruses.

Authors:  A Rösen-Wolff; T Ben-Hur; Y Becker; G Darai
Journal:  Virus Res       Date:  1988-06       Impact factor: 3.303

4.  Ribonucleic acid isolated by cesium chloride centrifugation.

Authors:  V Glisin; R Crkvenjakov; C Byus
Journal:  Biochemistry       Date:  1974-06-04       Impact factor: 3.162

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Genetic stability of equine arteritis virus during horizontal and vertical transmission in an outbreak of equine viral arteritis.

Authors:  Udeni B R Balasuriya; Jodi F Hedges; Steven A Nadler; William H McCollum; Peter J Timoney; N James MacLachlan
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

7.  Open reading frame 1a-encoded subunits of the arterivirus replicase induce endoplasmic reticulum-derived double-membrane vesicles which carry the viral replication complex.

Authors:  K W Pedersen; Y van der Meer; N Roos; E J Snijder
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Identification and mapping of the UL56 gene transcript of herpes simplex virus type 1.

Authors:  A Rösen-Wolff; G Darai
Journal:  Virus Res       Date:  1991-03       Impact factor: 3.303

9.  ORF1a-encoded replicase subunits are involved in the membrane association of the arterivirus replication complex.

Authors:  Y van der Meer; H van Tol; J K Locker; E J Snijder
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Identification of a neutralization site in the major envelope glycoprotein (GL) of equine arteritis virus.

Authors:  U B Balasuriya; N J Maclachlan; A A De Vries; P V Rossitto; P J Rottier
Journal:  Virology       Date:  1995-03-10       Impact factor: 3.616

View more
  3 in total

1.  Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus.

Authors:  M Giese; U Bahr; N J Jakob; R Kehm; M Handermann; H Müller; T H Vahlenkamp; C Spiess; T H Schneider; G Schusse; G Darai
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

2.  A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses.

Authors:  Ali Azizi; Susan Aucoin; Helina Tadesse; Rita Frost; Masoud Ghorbani; Catalina Soare; Turaya Naas; Francisco Diaz-Mitoma
Journal:  Genet Vaccines Ther       Date:  2005-08-22

Review 3.  Equine arteritis virus.

Authors:  Udeni B R Balasuriya; Yun Young Go; N James MacLachlan
Journal:  Vet Microbiol       Date:  2013-07-03       Impact factor: 3.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.